

NORWAY

Recent and planned developments in pharmaceutical policies 2014

Policies related to high cost medicines

D E V E L O P M E N T S	Changes in pricing	Changes in reimbursement
	<i>No changes.</i>	<p><i>Changes regarding reimbursement of medicines for hepatitis C, as of the 1st of November:</i></p> <p><i>Reimbursement restricted to members of the National Insurance Scheme</i></p> <p><i>Prescription by specialist</i></p> <p><i>Reimbursement only by individual application (except for ribavirin and peginterferone)</i></p> <p><i>Costeffectiveness of medicine will be evaluated by the NOMA</i></p>
	Other changes	
	<i>No changes</i>	
S P E C I A L T O P I C	High cost medicines	
	<p><i>A lot of public debate going on regarding high cost medicines for cancer treatment in hospitals. Debate concerning prioritization and how decisions are made. The new role of the NOMA (to evaluate costeffectiveness of hospital medicines) is being questioned.</i></p> <p><i>Criticism that decision process is not open: But the pharmaceutical companies demands secrecy about prices. And the price is part of the decision!</i></p> <p><i>The Norheim-commission (appointed by the Government) has recently published a report regarding prioritization in health care. Some changes are proposed that may influence the current situation. The age of the patient may play some role in the prioritization if the proposal is put into practice.</i></p>	